Overview

An Open-label Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease.

Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) and is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TB006. The total study duration for each participant will be up to approximately 113 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
TrueBinding, Inc.